Hanmi Pharm (KRX:128940) said Genentech has terminated a 2016 license agreement for belvarafenib, returning the drug's rights to the South Korean pharmaceutical company, according to a Friday South Korean bourse filing
The termination will take effect Dec. 27. Hanmi will retain the US$80 million upfront payment previously received from Genentech under the agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.